Quantcast

Latest Antiretroviral drug Stories

2014-06-12 08:28:09

CORK, Ireland, June 12, 2014 /PRNewswire/ -- Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY(R)) as the sole active ingredients for the maintenance treatment of people living with Human...

2014-06-10 08:29:37

Key findings point to significant differences between treated and untreated people living with HIV RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced new survey data that provide important insights that may help explain why HIV treatment rates remain low in the United States. Findings from the online survey, conducted by Harris Interactive on behalf of ViiV Healthcare in 2013, reveal gaps in knowledge about HIV and its treatment among diagnosed but...

2014-05-30 08:24:46

First Clinical Application of Genome Editing Technology in Hematopoietic Stem/Progenitor Cells RICHMOND, Calif., May 30, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN)...

2014-05-28 23:15:08

Professor Mark Wainberg from McGill University in Montreal shows that Dolutegravir rarely selects for resistance mutations and when they occur, HIV growth is impaired. Toulon, Var, France (PRWEB) May 28, 2014 Professor Mark Wainberg stated at the ISHEID that "Dolutegravir resistance is very difficult to obtain in vitro" and that this situation is unique among other antiretrovirals. A New Mechanism of Resistance Selection Actually, Dolutegravir is the last approved integrase...

2014-05-21 12:16:10

IQWiG Added benefit based on fewer side effects / no data for adolescents and pretreated adults who do not require integrase inhibitors Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality...

2014-05-19 09:55:53

University of Pittsburgh Schools of the Health Sciences The first direct proof of a long-suspected cause of multiple HIV-related health complications was recently obtained by a team led by the University of Pittsburgh Center for Vaccine Research (CVR). The finding supports complementary therapies to antiretroviral drugs to significantly slow HIV progression. The study, which will be published in the June issue of the Journal of Clinical Investigation and is available online, found that...

2014-05-16 23:05:57

The CDC’s Guidelines Expand the Pool of Patients Who Should Be Educated About PrEP Boston, MA (PRWEB) May 16, 2014 Fenway Health and The Fenway Institute strongly support the May 14 recommendations issued by the United States Centers for Disease Control and Prevention on the use of pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP is a proven tool for preventing HIV infection, reducing chances of infection by up to 92% according to several studies, including the iPrex study that...

Researcher Finds Soy Sauce Molecule May Unlock Drug Therapy For HIV Patients
2014-05-05 03:45:36

Jeff Sossamon / Roger Meissen, University of Missouri Compounds can be 70 times more potent than Tenofovir, a first-line HIV regimen For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications. Virologists at the University of Missouri now are testing the next generation of medications that stop HIV from...

2014-05-02 10:06:07

Enzyme's double-edged sword may soon be sheathed Johns Hopkins biochemists have figured out what is needed to activate and sustain the virus-fighting activity of an enzyme found in CD4+ T cells, the human immune cells infected by HIV. The discovery could launch a more effective strategy for preventing the spread of HIV in the body with drugs targeting this enzyme, they say. A summary of their work was published online on April 21 in the journal Proceedings of the National Academy of...

2014-05-01 20:24:08

HealthHIV's Third Annual State of HIV Primary Care National Survey Identifies Significant Training Needs and Barriers to Quality Care WASHINGTON, May 1, 2014 /PRNewswire-USNewswire/ -- Primary care providers who provide clinical HIV care (HIV PCPs) are experiencing rising HIV caseloads from newly insured patients under the Patient Protection and Affordable Care Act (PPACA), according to a national survey released today by HealthHIV. Forty percent of those surveyed say that the number of...


Latest Antiretroviral drug Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »
Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'karpos', fruit.
Related